NCT02385097View on ClinicalTrials.gov

Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block

PHASE3CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Axillary Nerve Block
Interventions
DRUG

Chloroprocaine HCl 2%

Single Administration (20mL) by Axillary Nerve Route

DRUG

Ropivacaine 0.75%

Single Administration (20mL) by Axillary Nerve Route

Trial Locations (1)

CH-6929

Claudio Camponovo, Gravesano

All Listed Sponsors
collaborator

Cross S.A.

INDUSTRY

lead

Sintetica SA

INDUSTRY

NCT02385097 - Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block | Biotech Hunter | Biotech Hunter